The Tablet in the Recliner: What the Ketamine Industry Got Wrong, and Why the Science Agrees
A client came to my practice after completing a full series of ketamine infusions elsewhere. She got the drug. She didn't get the therapy. This post examines why the mill model fails clinically, what the neuroscience says about integration and the neuroplasticity window, and why the industry's regulatory reckoning is overdue.
Jan 27
/
Peter H Addy
She came to my office after completing a full series at a ketamine clinic. Six infusions. Each time, she settled into a recliner, tablet in hand — could watch videos, play games, listen to whatever she wanted. A nurse checked in regularly. Nobody discussed what she might encounter during the sessions, or what to do with it afterward. She had major depression and PTSD. She left disappointed, confused, let down.
She wasn't unusual. I've seen this pattern more than once: people who got the drug and not the therapy, and then wondered why they didn't get better.
She wasn't unusual. I've seen this pattern more than once: people who got the drug and not the therapy, and then wondered why they didn't get better.
A Industry That Scaled by Cutting the Expensive Parts
The U.S. ketamine clinic market grew from fewer than 100 clinics in 2015 to over 1,500 by 2024, reaching an estimated $3.4 billion by 2023. That growth happened largely in a regulatory vacuum — there is still no federal framework specifying how a ketamine clinic must operate. None. The DEA regulates ketamine as a Schedule III controlled substance, which means record-keeping and storage requirements, but nothing about what happens to the person in the chair.
That vacuum got filled by the market. And the market, predictably, solved for throughput.
The model that scaled fastest was the one that extracted the billable drug event from the actual labor of treating someone. Brief intake questionnaire, infusion series, maybe a follow-up call. The clinical relationship — the careful screening, the preparation sessions, the therapeutic presence during the experience, the real integration work afterward — those things take time. Time compresses margin. So they got cut.
This is not a design flaw. It is commodified healthcare functioning exactly as intended.
That vacuum got filled by the market. And the market, predictably, solved for throughput.
The model that scaled fastest was the one that extracted the billable drug event from the actual labor of treating someone. Brief intake questionnaire, infusion series, maybe a follow-up call. The clinical relationship — the careful screening, the preparation sessions, the therapeutic presence during the experience, the real integration work afterward — those things take time. Time compresses margin. So they got cut.
This is not a design flaw. It is commodified healthcare functioning exactly as intended.
What the Science Actually Says About Integration
The clinical argument for treating ketamine as more than a drug infusion isn't just intuitive — it's mechanistically grounded. And it's worth understanding why, because it changes how we think about what those "extra" sessions actually do.
Ketamine works through several converging mechanisms. As an NMDA receptor antagonist, it produces rapid antidepressant effects, often within hours. But its sustained effects appear to involve something more consequential: the induction of synaptogenesis and neuroplasticity, particularly in the prefrontal cortex and hippocampus — precisely the regions atrophied by chronic depression and trauma.
Research reviewed by Muscat and colleagues synthesizes several decades of findings across five distinct mechanisms of action: NMDA receptor modulation, neuroplastogenic effects, anti-inflammatory activity, induction of high-entropy brain states, and the subjective psychedelic experience itself. Their key clinical argument: peak neuroplasticity — specifically, synaptogenesis — doesn't occur during the infusion. It peaks at 24–48 hours post-treatment.
That's when the integration session should happen.
If you send someone home with no framework, no therapeutic support, no structure for metabolizing what they just experienced, they're spending that neuroplastic window scrolling their phone. The brain is primed to form new pathways. Whether those pathways are adaptive depends substantially on what's happening in the psychological environment.
The Muscat paper also makes a pointed argument about set and setting that runs directly counter to the "do whatever you want with your tablet" model. The physical environment, the therapist's presence, and even the music program matter — not as comfort measures, but as clinical variables that shape the quality and direction of the dissociative experience. They recommend pre-selected, curated music (instrumental, emotionally evocative, varied in tempo) rather than whatever happens to be in the patient's Spotify queue, because the music isn't background noise — it's part of the therapeutic milieu. Importantly, they argue that the dissociative and psychedelic dimensions of the ketamine experience shouldn't be suppressed or bypassed. Evidence suggests that the intensity of altered states correlates with antidepressant outcomes, and that the experience of something meaningful or transcendent during treatment may be a key mechanism — not just a side effect to manage away.
The clinical outcomes data is consistent with this. A 2024 retrospective effectiveness study across eleven KAP clinics found large, sustained treatment effects at three and six months post-treatment for depression, anxiety, and PTSD — in a model that combined guided ketamine sessions with dedicated integration visits. The protocol was explicit: integration wasn't an add-on. It was built into the treatment architecture.
Sending someone into a dissociative state with no preparation and no integration isn't a neutral clinical choice. It's not personalized care. It's an abdicated responsibility dressed up as patient autonomy.
Ketamine works through several converging mechanisms. As an NMDA receptor antagonist, it produces rapid antidepressant effects, often within hours. But its sustained effects appear to involve something more consequential: the induction of synaptogenesis and neuroplasticity, particularly in the prefrontal cortex and hippocampus — precisely the regions atrophied by chronic depression and trauma.
Research reviewed by Muscat and colleagues synthesizes several decades of findings across five distinct mechanisms of action: NMDA receptor modulation, neuroplastogenic effects, anti-inflammatory activity, induction of high-entropy brain states, and the subjective psychedelic experience itself. Their key clinical argument: peak neuroplasticity — specifically, synaptogenesis — doesn't occur during the infusion. It peaks at 24–48 hours post-treatment.
That's when the integration session should happen.
If you send someone home with no framework, no therapeutic support, no structure for metabolizing what they just experienced, they're spending that neuroplastic window scrolling their phone. The brain is primed to form new pathways. Whether those pathways are adaptive depends substantially on what's happening in the psychological environment.
The Muscat paper also makes a pointed argument about set and setting that runs directly counter to the "do whatever you want with your tablet" model. The physical environment, the therapist's presence, and even the music program matter — not as comfort measures, but as clinical variables that shape the quality and direction of the dissociative experience. They recommend pre-selected, curated music (instrumental, emotionally evocative, varied in tempo) rather than whatever happens to be in the patient's Spotify queue, because the music isn't background noise — it's part of the therapeutic milieu. Importantly, they argue that the dissociative and psychedelic dimensions of the ketamine experience shouldn't be suppressed or bypassed. Evidence suggests that the intensity of altered states correlates with antidepressant outcomes, and that the experience of something meaningful or transcendent during treatment may be a key mechanism — not just a side effect to manage away.
The clinical outcomes data is consistent with this. A 2024 retrospective effectiveness study across eleven KAP clinics found large, sustained treatment effects at three and six months post-treatment for depression, anxiety, and PTSD — in a model that combined guided ketamine sessions with dedicated integration visits. The protocol was explicit: integration wasn't an add-on. It was built into the treatment architecture.
Sending someone into a dissociative state with no preparation and no integration isn't a neutral clinical choice. It's not personalized care. It's an abdicated responsibility dressed up as patient autonomy.
A Regulatory Reckoning That Doesn't Care About the Tablet
The era of unregulated ketamine clinic growth is ending, and not gracefully.
The DEA is now targeting ketamine providers through record-keeping inspections rather than diversion charges — and because DEA record-keeping regulations are, as healthcare attorneys who've defended these cases describe them, genuinely vague and confusing, providers can find themselves in enforcement actions without having done anything intentionally wrong. The DEA doesn't need to prove intent. Deficient records are sufficient.
Federal prosecutors charged two St. Louis physicians in 2024 with conspiracy to unlawfully distribute controlled substances and healthcare fraud — the core allegation being absentee medical directorship: ketamine administered under one physician's DEA registration while that physician wasn't present, and Medicare billed for services that were minimal or nonexistent. Telemedicine prescribing flexibilities have been extended through December 31, 2026, but there is still no permanent framework. That extension was granted, in regulators' own words, specifically to avoid disrupting care while rules are finalized — which is another way of saying the rules aren't finalized.
Regulatory scrutiny focuses on documentation, individualized treatment plans, and physician supervision — not on whether anyone processed anything during those 45 minutes of dissociation. The DEA does not care about the tablet.
But here's what's worth naming for clinicians doing KAP carefully: your thorough intake, your preparation sessions, your actual integration work — these are simultaneously clinically sound, ethically necessary, and now legally distinguishing. The paper trail of doing it right is the same paper trail that keeps you out of a record-keeping investigation. That's a strange kind of vindication. It's still real.
The DEA is now targeting ketamine providers through record-keeping inspections rather than diversion charges — and because DEA record-keeping regulations are, as healthcare attorneys who've defended these cases describe them, genuinely vague and confusing, providers can find themselves in enforcement actions without having done anything intentionally wrong. The DEA doesn't need to prove intent. Deficient records are sufficient.
Federal prosecutors charged two St. Louis physicians in 2024 with conspiracy to unlawfully distribute controlled substances and healthcare fraud — the core allegation being absentee medical directorship: ketamine administered under one physician's DEA registration while that physician wasn't present, and Medicare billed for services that were minimal or nonexistent. Telemedicine prescribing flexibilities have been extended through December 31, 2026, but there is still no permanent framework. That extension was granted, in regulators' own words, specifically to avoid disrupting care while rules are finalized — which is another way of saying the rules aren't finalized.
Regulatory scrutiny focuses on documentation, individualized treatment plans, and physician supervision — not on whether anyone processed anything during those 45 minutes of dissociation. The DEA does not care about the tablet.
But here's what's worth naming for clinicians doing KAP carefully: your thorough intake, your preparation sessions, your actual integration work — these are simultaneously clinically sound, ethically necessary, and now legally distinguishing. The paper trail of doing it right is the same paper trail that keeps you out of a record-keeping investigation. That's a strange kind of vindication. It's still real.
The Political Argument I Won't Soften
The patients hurt worst by the mill model are not randomly distributed. People who can afford $600 per session in cash — because insurance doesn't cover this — are overwhelmingly affluent, white, and already-resourced. The patients most likely to be funneled through a high-throughput telemedicine platform are those with fewer options, less ability to advocate for themselves, and histories of trauma that make a dissociative experience without support not just unhelpful but potentially retraumatizing.
The psychedelic therapy industry has marketed itself on equity and healing. It has largely delivered a boutique product priced for venture capital returns.
Ketamine, unlike psilocybin or MDMA, is already legal and relatively inexpensive to produce. It is the only psychedelic-class medicine currently accessible to most clinicians working in standard practice. That makes how it's deployed a genuine healthcare equity question — not just a clinical or regulatory one.
Doing KAP right — with preparation, therapeutic presence, and integration — is more expensive and more labor-intensive than running someone through a series of supervised infusions. But it also works better. The evidence is clear. And if we're building a field, the argument that ethical practice and effective practice are the same thing is the one worth making loudly, before the market finishes defining the standard of care for us.
The psychedelic therapy industry has marketed itself on equity and healing. It has largely delivered a boutique product priced for venture capital returns.
Ketamine, unlike psilocybin or MDMA, is already legal and relatively inexpensive to produce. It is the only psychedelic-class medicine currently accessible to most clinicians working in standard practice. That makes how it's deployed a genuine healthcare equity question — not just a clinical or regulatory one.
Doing KAP right — with preparation, therapeutic presence, and integration — is more expensive and more labor-intensive than running someone through a series of supervised infusions. But it also works better. The evidence is clear. And if we're building a field, the argument that ethical practice and effective practice are the same thing is the one worth making loudly, before the market finishes defining the standard of care for us.
